Cargando…

Treatment response in COPD: does FEV(1) say it all? A post hoc analysis of the CRYSTAL study

The association between clinically relevant changes in patient-reported outcomes (PROs) and forced expiratory volume in 1 s (FEV(1)) in patients with chronic obstructive pulmonary disease (COPD) has rarely been investigated. Using CRYSTAL, a 12-week open-label study in symptomatic, nonfrequently exa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kostikas, Konstantinos, Greulich, Timm, Mackay, Alexander J., Lossi, Nadine S., Aalamian-Mattheis, Maryam, Nunez, Xavier, Pagano, Veronica A., Patalano, Francesco, Clemens, Andreas, Vogelmeier, Claus F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387992/ https://www.ncbi.nlm.nih.gov/pubmed/30815470 http://dx.doi.org/10.1183/23120541.00243-2018

Ejemplares similares

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study
por: Greulich, Timm, et al.
Publicado: (2018)

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
por: Vogelmeier, Claus F., et al.
Publicado: (2017)

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients
por: Kostikas, Konstantinos, et al.
Publicado: (2020)

The asthma–COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease?
por: Kostikas, Konstantinos, et al.
Publicado: (2016)

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
por: Marin, Jose M, et al.
Publicado: (2016)

Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD
por: Kostikas, Konstantinos, et al.
Publicado: (2018)

Patient-Reported Outcomes (PROs) in COPD Clinical Trials: Trends and Gaps
por: Afroz, Nuzhat, et al.
Publicado: (2020)

A year in the life of German patients with COPD: the DACCORD observational study
por: Buhl, Roland, et al.
Publicado: (2016)

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
por: Vogelmeier, Claus F, et al.
Publicado: (2018)

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
por: Vogelmeier, Claus, et al.
Publicado: (2017)

Health-related quality of life associates with change in FEV(1) in COPD: results from the COSYCONET cohort
por: Lutter, Johanna I., et al.
Publicado: (2020)

Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®)
por: Vogelmeier, Claus F., et al.
Publicado: (2015)

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
por: Vestbo, Jørgen, et al.
Publicado: (2019)

COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV(1) – a post-hoc analysis of pooled data
por: Chai, Chee-Shee, et al.
Publicado: (2023)

Pulmonary function testing in COPD: looking beyond the curtain of FEV1
por: Kakavas, Sotirios, et al.
Publicado: (2021)

High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients – a retrospective analysis
por: Greulich, Timm, et al.
Publicado: (2020)

Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study
por: Mackay, Alexander J., et al.
Publicado: (2020)

Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1)
por: Lange, Peter, et al.
Publicado: (2016)

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations
por: Vogelmeier, Claus F., et al.
Publicado: (2019)

COPD assessment test and FEV(1): do they predict oxygen uptake in COPD?
por: Carvalho-Jr, Luiz Carlos S, et al.
Publicado: (2018)

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial
por: Watz, Henrik, et al.
Publicado: (2018)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort
por: Greulich, Timm, et al.
Publicado: (2018)

The Distribution of Alpha-1 Antitrypsin Genotypes Between Patients with COPD/Emphysema, Asthma and Bronchiectasis
por: Veith, Martina, et al.
Publicado: (2020)

Inflammatory and immunological profiles in patients with COPD: relationship with FEV (1) reversibility
por: Queiroz, Cleriston Farias, et al.
Publicado: (2016)

Low FEV1 Is Associated With Increased Risk Of Cachexia In COPD Patients
por: Mokari-Yamchi, Amin, et al.
Publicado: (2019)

FVC, but not FEV(1,) is associated with clinical outcomes of asthma-COPD overlap
por: An, Tai Joon, et al.
Publicado: (2022)

Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD
por: Zhumagaliyeva, Ardak, et al.
Publicado: (2017)

Validity and Usability of Physical Activity Monitoring in Patients with Chronic Obstructive Pulmonary Disease (COPD)
por: Boeselt, Tobias, et al.
Publicado: (2016)

Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients
por: Karl, Florian M., et al.
Publicado: (2017)

Novel protein biomarkers for pneumonia and acute exacerbations in COPD: a pilot study
por: Jung, Anna Lena, et al.
Publicado: (2023)

Exacerbations of COPD
por: Viniol, Christian, et al.
Publicado: (2018)

Fixed Cut-Off for FEV1/FEV6 and FEV6 in Detection of Obstructive and Restrictive Patterns
por: Aghili, Rokhsareh, et al.
Publicado: (2013)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
por: Rodrigo, Gustavo J, et al.
Publicado: (2017)

Beyond FEV(1) in COPD: a review of patient-reported outcomes and their measurement
por: Jones, Paul, et al.
Publicado: (2012)

Risk factors for FEV(1) decline in mild COPD and high-risk populations
por: Chen, Shujing, et al.
Publicado: (2017)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
por: Vogelmeier, Claus, et al.
Publicado: (2016)

A randomized clinical trial to assess the influence of a three months training program (Gym-based individualized vs. Calisthenics-based non-invidualized) in COPD-patients
por: Greulich, Timm, et al.
Publicado: (2014)

Benefits of whole body vibration training in patients hospitalised for COPD exacerbations - a randomized clinical trial
por: Greulich, Timm, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v1prj9j7bn2pf4dfjg2b6s1cn0